BioPharmSignal logoBioPharmSignal

Biotech News

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease

Neurocrine Biosciences (NBIX)Neurocrine BiosciencesClinical readout

SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 (NBI-'567) in adults with mild to moderate Alzheimer's disease. NBI-'567 is an orally administered, M1/M4 (M1

Related news

NBIXNeurocrine Biosciences2026-08-07 12:30 EST

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

NBIXNeurocrine Biosciences2026-08-12 12:30 EST

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

ABOSAcumen Pharmaceuticals2026-10-22 11:30 EST

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

NGENNervGen Pharma2026-10-12 11:15 EST

NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury

VKTXViking Therapeutics2026-10-14 11:05 EST

Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity

JNJJohnson & Johnson2026-10-19 12:23 EST

Johnson & Johnson announces new TREMFYA® (guselkumab) data showing durable 3-year outcomes in moderate to severe Crohn’s disease and expanding evidence in perianal fistula

VKTXViking Therapeutics2026-10-06 11:05 EST

Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity

ALKSAlkermes plc2026-09-21 11:00 EST

Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

AXSMAxsome2026-08-31 11:00 EST

Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

XENEXenon2026-08-26 20:01 EST

Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026

View all latest news

Neurocrine Biosciences

Neuroscience and Endocrinology Portfolio Neurocrine Biosciences discovers, develops and commercializes medicines for neuropsychiatric, neurological, endocrine and immunological disorders. Its business combines several first-in-class commercial products with a deep mid- and late-stage pipeline. Commercial Medicines The portfolio includes...

Recent company news

NBIXNeurocrine Biosciences2026-10-22 20:05 EST

Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome

NBIXNeurocrine Biosciences2026-10-20 12:30 EST

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease

NBIXNeurocrine Biosciences2026-10-16 12:30 EST

Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia

NBIXNeurocrine Biosciences2026-10-12 20:01 EST

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results

NBIXNeurocrine Biosciences2026-09-30 12:30 EST

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference

Stock data

Close
141.31 USD
Market cap
15.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States